The purpose of this study is to find out if starting anti-retroviral therapy (ART) above 500 cluster-of-differentiation-4 (CD4)+ cells/milliliter (mL) ('early ART group') is better at reducing the stiffness of arteries than waiting to start ART until the CD4+ drops below 350 cells/mL ('deferred ART group'). Artery stiffness has been associated with an increased risk of cardiovascular (heart) disease, and could be useful as an earlier indicator of heart disease. In this study, the stiffness of arteries will be measured at study entry, months 4, 8, 12, and annually thereafter, using a tonometer on the participant's forearm.

Inability to ascertain waveform measurements that can be analyzed, i.e. atrial fibrillation

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01776151

Locations

United States, Michigan

Henry Ford Health System

Detroit, Michigan, United States, 48202

Sponsors and Collaborators

University of Minnesota - Clinical and Translational Science Institute

Investigators

Study Chair:

Jason V Baker, MD

University of Minnesota - Clinical and Translational Science Institute

Study Chair:

Daniel Duprez, MD, PhD

University of Minnesota - Clinical and Translational Science Institute